Sengupta N, Siddiqui Emad, Mumtaz Faiz H
Department of Urology, Chase Farm Hospital, The Ridgeway, Enfield EN2 8JL, England.
J R Soc Promot Health. 2004 Sep;124(5):228-9. doi: 10.1177/146642400412400520.
Bladder cancer is the fifth most common malignancy in Europe and the fourth most common malignancy in the United States. It affects one in 4000 people and accounts for 5% of all diagnosed cancers. The peak incidence is in the fifth and seventh decade. There is a strong association between smoking and bladder cancer. Smokers have a fourfold higher incidence of developing bladder cancer than the general population. The disease has a spectrum of clinical severity varying from superficial bladder cancer to muscle invasive or metastatic disease which carries a poor prognosis. Currently the superficial form of the disease is managed by endoscopic resection of the tumour, often followed by the instillation into the bladder of cytotoxic agents. Due to the tendency of bladder cancer to recur repeated cystoscopies and resections are often required. Because of this, one of the main thrusts of research is to find a way of preventing the progression from superficial disease to muscle invasive and metastatic bladder cancer.
膀胱癌是欧洲第五大常见恶性肿瘤,在美国是第四大常见恶性肿瘤。每4000人中就有1人受其影响,占所有确诊癌症的5%。发病高峰在50多岁和70多岁。吸烟与膀胱癌之间存在密切关联。吸烟者患膀胱癌的几率比普通人群高四倍。该疾病的临床严重程度范围较广,从浅表性膀胱癌到肌肉浸润性或转移性疾病,后者预后较差。目前,该疾病的浅表形式通过肿瘤的内镜切除进行治疗,通常随后向膀胱内灌注细胞毒性药物。由于膀胱癌有复发的倾向,常常需要反复进行膀胱镜检查和切除术。因此,研究的主要方向之一是找到一种方法来防止疾病从浅表性发展为肌肉浸润性和转移性膀胱癌。